Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pancreatic neuroendocrine tumor - Clinical Profile, Genes & Research | Kisho | Kisho

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for pancreatic neuroendocrine tumor. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for pancreatic neuroendocrine tumor, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for pancreatic neuroendocrine tumor. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Foslinanib	Foslinanib	TaiRx, Inc.	2025	—	Designated

Gene therapy approaches for pancreatic neuroendocrine tumor have been reported in the published literature.

Clinical Trials

42 trials found

Explore Trials

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

42 clinical trials registered, 8 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE4, 3 PHASE3, 14 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT00830557](https://clinicaltrials.gov/study/NCT00830557)	Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders	—	Mayo Clinic	RECRUITING
[NCT04119024](https://clinicaltrials.gov/study/NCT04119024)	Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	PHASE1	Anusha Kalbasi	RECRUITING
[NCT06523582](https://clinicaltrials.gov/study/NCT06523582)	Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	—	Universidad Nacional Autonoma de Mexico	RECRUITING
[NCT07439757](https://clinicaltrials.gov/study/NCT07439757)	AI-Powered Precision Decision-Making for Pancreatic Diseases	—	Changhai Hospital	RECRUITING
[NCT06592989](https://clinicaltrials.gov/study/NCT06592989)	A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET	—	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	RECRUITING

294 publications have been identified in PubMed for pancreatic neuroendocrine tumor. Kisho has analyzed 154 by research type. Research spans Case Report / Case Series (21%), Basic Science / Preclinical (19%), and Diagnostic / Biomarker (18%).

Research Type	Count	% of Total
Patient case studies	33	21%
Laboratory research	29	19%
Testing and diagnosis research	28	18%
Research summaries	24	16%
Clinical study results	19	12%
Disease patterns and progression	13

Recent Publications

Aliberti G (2026). [PMID: 41633869](https://pubmed.ncbi.nlm.nih.gov/41633869/). *Diagn Interv Imaging*. [Other]
Xu L (2026). [PMID: 42160318](https://pubmed.ncbi.nlm.nih.gov/42160318/). *Endocr Relat Cancer*. [Basic Science / Preclinical]
Singhi AD (2026). [PMID: 41388172](https://pubmed.ncbi.nlm.nih.gov/41388172/). *Ann Surg Oncol*. [Clinical Trial Publication]
Cai Z (2026). [PMID: 41591671](https://pubmed.ncbi.nlm.nih.gov/41591671/). *Discov Oncol*. [Basic Science / Preclinical]
Choi GW (2026). [PMID: 41680035](https://pubmed.ncbi.nlm.nih.gov/41680035/). *Pancreatology*. [Diagnostic / Biomarker]
Expert Panel on Gastrointestinal Imaging (2026). [PMID: 41823937](https://pubmed.ncbi.nlm.nih.gov/41823937/). *J Am Coll Radiol*. [Review / Meta-Analysis]
Kjær MB (2026). [PMID: 41761637](https://pubmed.ncbi.nlm.nih.gov/41761637/). *J Neuroendocrinol*. [Basic Science / Preclinical]
Zhang L (2026). [PMID: 41642264](https://pubmed.ncbi.nlm.nih.gov/41642264/). *J Am Coll Surg*. [Epidemiology / Natural History]
Lamback E (2026). [PMID: 42007244](https://pubmed.ncbi.nlm.nih.gov/42007244/). *JCEM Case Rep*. [Case Report / Case Series]
Watanabe H (2026). [PMID: 41051970](https://pubmed.ncbi.nlm.nih.gov/41051970/). *Int J Surg Pathol*. [Review / Meta-Analysis]

Kisho

pancreatic neuroendocrine tumor

Overview

Diagnosis

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Treatment

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Latest News & Developments

Robotic subtotal pancreatectomy for multifocal neuroendocrine tumour of the pancreas.

Pancreatic Neuroendocrine Tumor in Lynch Syndrome: Expanding the Tumor Spectrum of Mismatch Repair Deficiency.

Metachronous Primary Pancreatic Neuroendocrine Tumor and Adenocarcinoma: A Case Report.

pancreatic neuroendocrine tumor

Overview

Diagnosis

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Treatment

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Latest News & Developments

Robotic subtotal pancreatectomy for multifocal neuroendocrine tumour of the pancreas.

Pancreatic Neuroendocrine Tumor in Lynch Syndrome: Expanding the Tumor Spectrum of Mismatch Repair Deficiency.

Metachronous Primary Pancreatic Neuroendocrine Tumor and Adenocarcinoma: A Case Report.